Piper Jaffray analyst Michael Lavery maintained a Buy rating on Canopy Growth Corp (CGC) today and set a price target of $36.00. The company’s shares closed last Monday at $20.35, close to its 52-week low of $17.89.
According to TipRanks.com, Lavery is currently ranked with no stars on a 0-5 star ranking scale, with an average return of -9.0% and a 32.1% success rate. Lavery covers the Consumer Goods sector, focusing on stocks such as Mondelez International, Post Holdings Inc, and Altria Group Inc.
Canopy Growth Corp has an analyst consensus of Moderate Buy, with a price target consensus of $34.77.
See today’s analyst top recommended stocks >>
The company has a one-year high of $52.74 and a one-year low of $17.89. Currently, Canopy Growth Corp has an average volume of 4.74M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Canopy Growth Corp. engages in the production and sale of medical cannabis. The company offers products including oils and concentrates, soft gel capsules and hemp. It focuses on the treatment of chronic pain, seizures, muscle spasms, nausea, and loss of appetite.
Read More on CGC:
